IP Verse

Shire Human Genetic Therapies opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Shire Human Genetic Therapies

Patent Number:
EP2708559
Title:
Antigen-Binding Molecule Capable Of Binding To Two Or More Antigen Molecules Repeatedly
Applicant:
CHUGAI SEIYAKU KABUSHIKI KAISHA
Opposition Date:
Dec 21, 2018
Patent Number:
EP2708558
Title:
Antigen-Binding Molecule Capable Of Binding To Two Or More Antigen Molecules Repeatedly
Applicant:
CHUGAI SEIYAKU KABUSHIKI KAISHA
Opposition Date:
Dec 20, 2018
Patent Number:
EP2552955
Title:
Antibodies With Modified Affinity To Fcrn That Promote Antigen Clearance
Applicant:
CHUGAI SEIYAKU KABUSHIKI KAISHA
Opposition Date:
Feb 5, 2018

Latest patents of Shire Human Genetic Therapies opposed by its competitors

Patent:
EP2858679
Grant Date:
Jun 5, 2024
Title:
Pulmonary Delivery Of Mrna To Non-Lung Target Cells
Oppositions:
1
Patent:
EP3626258
Grant Date:
Aug 4, 2021
Title:
Methods And Compositions For Cns Delivery Of Iduronate-2-Sulfatase
Oppositions:
1
Patent:
EP2970456
Grant Date:
May 19, 2021
Title:
Methods And Compositions For Delivering Mrna Coded Antibodies
Oppositions:
4
Patent:
EP3103469
Grant Date:
Dec 9, 2020
Title:
Cns Delivery Of Therapeutic Agents
Oppositions:
1
Patent:
EP3134506
Grant Date:
Aug 7, 2019
Title:
Methods For Purification Of Messenger Rna
Oppositions:
2
Patent:
EP3060303
Grant Date:
Nov 14, 2018
Title:
Mrna Therapy For Argininosuccinate Synthetase Deficiency
Oppositions:
1
Patent:
EP3122878
Grant Date:
Oct 24, 2018
Title:
Mrna Therapy For The Treatment Of Ocular Diseases
Oppositions:
1
Patent:
EP2867245
Grant Date:
Sep 12, 2018
Title:
Purification Of Iduronate-2-Sulfatase
Oppositions:
1
Patent:
EP2506857
Grant Date:
Feb 14, 2018
Title:
Delivery Of Mrna For The Augmentation Of Proteins And Enzymes In Human Genetic Diseases
Oppositions:
4

Competitors of Shire Human Genetic Therapies

WITHERS & ROGERS LLP

CHUGAI SEIYAKU KABUSHIKI KAISHA

BRADY, PAUL ANDREW

Want to track Shire Human Genetic Therapies?

Feel free to send us a message here and we will get back to you